Current News

Contact | Print version | Send article | RSS feed

Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into a Contract Services Agreement

05 Mar 2007 - Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, announced the company has entered into a Contract Services Agreement with Affectis Pharmaceuticals AG, of Munich, Germany.
 
Affectis has contracted Dalton for the manufacturing of preclinical tox material with potential for cGMP production. Affectis is an exciting addition to Dalton's portfolio of world wide clients. Dalton has first hand experience advancing compounds from a range of therapeutic areas including Alzheimer's, cardiovascular diseases, HIV, anti-aging and now also affective disorders.
 
"With this agreement, Affectis reaches an important milestone of advancing its P2X7 agonist program into pre-clinical development" said Herbert Stadler, CEO of Affectis. "Dalton's manufacturing know-how will help Affectis bring a novel antidepressant candidate into the clinic."